Bionpharma v. Silvergate Pharmaceuticals: Federal Circuit Appeal Voluntarily Dismissed
Bionpharma, Inc. voluntarily dismissed its Federal Circuit appeal against Silvergate Pharmaceuticals, Inc. after just 48 days, ending a challenge involving seven patents covering Epaned® enalapril maleate oral solution at 1 mg/mL. The public record is silent on whether dismissal was with or without prejudice.
Seven-patent enalapril appeal dropped in under two months at the Federal Circuit
Bionpharma, Inc. filed this infringement appeal at the Court of Appeals for the Federal Circuit on November 5, 2024, challenging Silvergate Pharmaceuticals, Inc. in connection with seven U.S. patents covering enalapril maleate oral solution at a proposed strength of 1 mg/mL — the formulation marketed as Epaned®. The patents span application numbers from US13/608658 through US16/003994, reflecting a layered portfolio of formulation and method claims built around the pediatric cardiovascular drug.
The appeal was voluntarily dismissed on December 23, 2024, just 48 days after filing. Voluntary dismissal at the appellate level is a procedural withdrawal by the moving party — here, Bionpharma — meaning the Federal Circuit issued no ruling on the merits of the underlying infringement claims. The basis of termination recorded is ‘Voluntary dismissal,’ but the public record does not specify whether the dismissal was with or without prejudice, leaving the door to future litigation potentially open.
The 48-day duration is notably short even for a voluntarily dismissed appeal, suggesting the decision to withdraw may have been driven by settlement discussions, a commercial resolution, or a strategic reassessment of the litigation position — none of which can be confirmed from public filings. What remains unknown is whether any side agreement accompanied the dismissal and whether Bionpharma retains the right to refile claims related to these seven patents.
Filing to Voluntary dismissal in 48 days
Appeal resolved in 48 days — well below the typical Federal Circuit disposition timeline of 12–18 months
Voluntarily dismissed: what the withdrawal means for both parties
Voluntary dismissal ends the appeal without a merits ruling
A voluntary dismissal at the Federal Circuit means the appellant — here, Bionpharma — elected to withdraw the appeal before the court adjudicated any substantive question. The Federal Circuit issued no opinion on claim construction, infringement, or validity. The underlying district court record and any prior rulings remain in place, but this appeal adds no new precedent.
No merits adjudicationWith or without prejudice? The public record is silent
A dismissal ‘with prejudice’ permanently bars the dismissed party from re-litigating the same claims; one ‘without prejudice’ preserves the right to refile. The basis of termination here records only ‘Voluntary dismissal’ — no prejudice qualifier is stated. This ambiguity is legally significant: it is unclear whether Bionpharma retains the ability to reassert claims tied to these seven enalapril maleate patents in future proceedings.
Prejudice status unconfirmedBionpharma exits the appeal with its position unresolved
By voluntarily withdrawing, Bionpharma avoids the risk of an adverse appellate ruling that could have established unfavourable precedent across its enalapril maleate claims. However, the company also foregoes any appellate vindication. Whether the withdrawal reflects a commercial resolution, a licensing arrangement, or a strategic pivot is not disclosed in the public record.
No appellate win or lossSilvergate avoids an adverse ruling but gains no affirmance
Silvergate Pharmaceuticals benefits from the cessation of appellate pressure without incurring the cost and risk of a full Federal Circuit briefing cycle. However, because no merits ruling was issued, Silvergate receives no appellate affirmance of its patent position that could be used offensively against future generic entrants. The enforceability of the seven patents remains tied entirely to prior district court proceedings.
Position preserved, not strengthenedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Bionpharma, Inc. | Company | Generic pharmaceutical company — appellant asserting seven enalapril maleate oral solution patentsSearch in Eureka ↗ |
| Defendant | Silvergate Pharmaceuticals, Inc. | Company | Specialty pharma company; appellee defending Epaned® enalapril maleate 1 mg/mL formulation rightsSearch in Eureka ↗ |
| Plaintiff counsel | Brian Murray | Attorney | Counsel for Bionpharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Charles A. Weiss | Attorney | Counsel for Bionpharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Holland & Knight, LLP | Law Firm | Representing Bionpharma, Inc.Search in Eureka ↗ |
| Defendant counsel | Jack B. Blumenfeld | Attorney | Counsel for Silvergate Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Silvergate Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge MitchellS. Goldberg | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The recorded verdict — ‘voluntarily dismissing appeal’ — confirms that Bionpharma elected to withdraw before any substantive Federal Circuit review commenced. This phrasing indicates a party-initiated procedural termination, not a court-ordered disposition. Because no merits opinion was issued, neither party can cite this proceeding as establishing or undermining the validity or infringement scope of any of the seven enalapril maleate patents. The legal posture of the portfolio is therefore unchanged by this appeal.
US9808442B2 and six further patents — enalapril maleate oral solution formulations
The seven patents in suit — led by US9808442B2 and spanning application families filed between 2012 and 2018 — collectively protect formulation, composition, and method-of-use aspects of enalapril maleate oral solution at 1 mg/mL, the active ingredient in Epaned®. Enalapril maleate is an ACE inhibitor used in the treatment of hypertension and heart failure, with the oral solution form particularly relevant for pediatric patients unable to swallow solid dosage forms. The portfolio’s multi-family structure is consistent with a strategy to create overlapping exclusivity across formulation variables, stability parameters, and administration methods.
The strategic depth of a seven-patent portfolio around a single oral solution concentration signals that the patent holder has invested heavily in creating durable exclusivity. For competitors, this means that designing around any single patent is unlikely to clear the landscape — each of the seven patents represents an independent barrier. The dispute between Bionpharma and Silvergate reflects the broader pattern of ANDA-driven pharmaceutical patent litigation where generic entrants challenge branded formulation portfolios at the Federal Circuit after adverse district court outcomes.
Should you run an FTO against the Epaned® enalapril maleate patent portfolio?
Any company developing, filing an ANDA for, or commercialising an enalapril maleate oral solution at or near 1 mg/mL should conduct a thorough freedom-to-operate analysis against all seven patents in this portfolio. The absence of a Federal Circuit merits ruling means no appellate claim construction has narrowed or invalidated any claim — each patent retains full presumptive validity. R&D teams formulating paediatric ACE inhibitor oral solutions should pay particular attention to stability, excipient selection, and dosing method claims.
PatSnap Eureka’s FTO Search Agent allows IP and R&D teams to map claim scope across all seven patent families simultaneously, flag expiry dates and any patent term extensions, and identify prior art that may support invalidity arguments. Rather than reviewing each patent in isolation, Eureka surfaces the claim-level overlap and prosecution history nuances that matter most for launch-readiness decisions in competitive pharmaceutical markets.
Run a freedom-to-operate analysis on US9808442B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in pharmaceutical formulation patent litigation
Cases involving voluntary dismissals and multi-patent portfolios at the Federal Circuit in ANDA-driven pharmaceutical oral solution disputes, including enalapril and related ACE inhibitor formulations.
What this case signals for the pharmaceutical patent IP landscape
Early voluntary dismissals at the Federal Circuit in ANDA-linked patent disputes often signal off-record resolution. Here is what IP teams should watch.
Ultra-short Federal Circuit appeals warrant settlement monitoring
A 48-day Federal Circuit appeal lifecycle — from filing to voluntary dismissal — is a strong indicator that parties reached an off-record resolution, whether commercial, licensing, or otherwise. IP teams tracking generic pharmaceutical entry timelines should treat such dismissals as potential signals of agreed market access terms rather than litigation defeats.
Seven-patent portfolio depth raises the FTO bar for enalapril maleate entrants
The breadth of the asserted portfolio — seven patents spanning multiple application families — reflects a layered exclusivity strategy around the Epaned® formulation. Any competitor or generic entrant considering enalapril maleate oral solution products at 1 mg/mL must conduct thorough FTO analysis across all seven patent numbers before product launch or ANDA filing.
Bionpharma v Silvergate — key questions answered
Bionpharma voluntarily dismissed its Federal Circuit appeal (Case No. 25-1149) against Silvergate Pharmaceuticals on December 23, 2024, just 48 days after filing on November 5, 2024. The appeal involved seven U.S. patents covering enalapril maleate oral solution at 1 mg/mL (Epaned®). No merits ruling was issued.
Seven patents were asserted: US9808442B2, US10039745B2, US8794749, US8454116, US10154987B2, US9669008B1, and US6955422. All relate to enalapril maleate oral solution formulations and methods of use, covering the Epaned® product at a proposed strength of 1 mg/mL.
The public record records only ‘Voluntary dismissal’ as the basis of termination — no prejudice qualifier is specified. This means it is unclear from available public filings whether Bionpharma is barred from refiling claims related to the seven enalapril maleate patents or retains the right to pursue future proceedings.
A voluntary dismissal means the Federal Circuit issued no opinion on the merits — no claim construction, infringement finding, or validity ruling. All seven asserted patents retain their full presumptive validity. The dismissal does not weaken or strengthen any party’s patent position; it simply ends the appeal without judicial resolution.
The 48-day duration between filing and dismissal is consistent with parties reaching an off-record resolution — potentially a licensing arrangement, market access agreement, or commercial settlement. It may also reflect a strategic reassessment of appellate prospects. The precise reason is not disclosed in the public record, and PatSnap cannot confirm any specific driver.
PatSnap Eureka searches patents and litigation data to answer instantly.